Well, good start... Do they will continue before end of 2012 (approximate start of sales in Europe)? So, proposed game tactics here: two steps down, two steps up and sell all ITMN holdings during and in between steps. Fund's analysts are promising giant sales in Europe and nobody asking why Japan sales were so modest and still declining. BTW, look at Pirfenidone chemical structure. It's simpler than aspirin, so why ITMN put so high price for this small molecule ($8.62 per 200 mg)? Do they think that Europe will pay so high price? GL to all shorts (they are wise people among this madness).